By: M. Alexander Otto, PA, MMSc From: medscape.com MRI can identify patients with HER2-positive breast cancer who don’t need a full course of neoadjuvant chemotherapy, letting them avoid the toxicity of unnecessary treatment while preserving 3-year event-free survival, new trial findings suggest. The study, published in The Lancet Oncology, found that patients had “excellent” outcomes even if they received only …
New approach better predicts chemotherapy response in patients with triple-negative breast cancer
Source: University of Texas M. D. Anderson Cancer Center From: news-medical.net Researchers at The University of Texas MD Anderson Cancer Center have developed a new computational approach designed to better account for changes in gene expression within tumors relative to their unique microenvironments. This approach outperformed current methods for predicting chemotherapy response in patients with triple-negative breast cancer (TNBC). The …
Is Enhertu Chemotherapy or Immunotherapy?
From: healthline.com Key takeaways Enhertu isn’t a typical chemotherapy or immunotherapy drug but rather a combination of chemotherapy and targeted therapy, known as an antibody-drug conjugate. Enhertu works by using an antibody to target specific proteins (HER2) on cancer cells and delivering a chemotherapy drug directly to those cells to hinder and destroy them. Enhertu is prescribed for specific types …
Adding Aprepitant to Chemo Extends Non-Luminal Breast Cancer Survival
By: Bridget Hoyt From: oncnursingnews.com The addition of the antiemetic aprepitant (Emend) to standard chemotherapy was linked to improved survival outcomes for patients with early non-luminal breast cancers, particularly those with triple-negative breast cancer, according to data published in the Journal of the National Cancer Institute.1 Stratified analyses demonstrated a significant improvement in distant disease-free survival (DDFS) and breast cancer-specific …
Olanzapine/Triplet Cuts Chemo-Induced Nausea, Vomiting in Breast Cancer
By: Roman Fabbricatore From: oncnursingnews.com Adding 5 mg of olanzapine to triplet antiemetic therapy entailing a NK-1 receptor antagonist, palonosetron (Aloxi), and dexamethasone yielded greater antiemetic efficacy compared with placebo for patients with breast cancer following prior treatment with anthracycline plus cyclophosphamide-based chemotherapy, according to data from a phase 3 trial (jRCT1031200134) published in Lancet Oncology. After a median follow-up …
Filling the Gap: Creating a Prognostic Staging System for Patients Treated With Neoadjuvant Chemotherapy
By: By David Winchester, MD From: docwirenews.com David Winchester, MD, City of Hope, had an instrumental role in the creation of the breast cancer staging system published in the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual. In this interview, Dr. Winchester discusses a major update to the AJCC breast cancer staging system, addressing a …
Is Chemotherapy Always Necessary for Early HER2‐Positive Breast Cancer?
By: Deborah L. Ungerleider, MD, FAAP From: medpagetoday.com Human epidermal growth factor receptor 2 (HER2), which is overexpressed in 15% to 20% of breast cancers, is known to be an adverse prognostic factor. Therapies targeting HER2 have improved long-term outcomes for patients, according to evidence from several clinical trials, but not without toxicity.1,2,3 Previous research, however, has shown no difference …
Cooling or Compressing Hands During Chemo Can Prevent Neuropathy
By: Liz Highleyman From: cancerhealth.com Women who wear frozen or tight-fitting gloves during taxane-based chemotherapy for breast cancer are less likely to develop painful peripheral neuropathy, according to research published in JAMA Oncology. While both methods were effective, compression is more accessible and may be better tolerated than cold temperature. Cytotoxic chemotherapy is an effective treatment for many types of …
De-Escalation of Neoadjuvant Chemoimmunotherapy May Be Feasible Option
By: Leah Lawrence From: docwirenews.com Lead-in nivolumab before neoadjuvant chemotherapy was not associated with a pathologic complete response (pCR) advantage compared with sequential nivolumab and chemotherapy for patients with early triple-negative breast cancer (TNBC), according to results of the Neo-N trial. However, the trial tested a 12-week regimen—compared with the current standard of 24 weeks—and showed high rates of pCR, …
What Is Neoadjuvant Chemotherapy for Breast Cancer?
From: healthline.com When chemotherapy is the first step in your breast cancer treatment, it’s called neoadjuvant therapy. Neoadjuvant therapiesTrusted Source are systemic therapies that come before a main treatment. Because there are several kinds of breast cancer, not everyone receives the same treatments in the same order. While neoadjuvant chemotherapy is a good option for some people with breast cancer, …